TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23422374
Drug: Paliperidone starting
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Paliperidone starting dose of 3 mg/d; subsequent dosing range of 3 to 6 mg/d for adolescents less than 51 kg and 3 to 12 mg/d for adolescents greater than or equal to 51 kg.
Study: 19856793
Drug: Isoxsuprine hydrochloride
Normalized name: Isoxsuprine Hydrochloride
DrugBank: Isoxsuprine (DB08941)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoxsuprine hydrochloride 90 mg
Study: 18705933
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (aspirin, dipyridamole or clopidogrel alone or in dual combination)
Study: 18705933
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (heparin followed by warfarin aiming for an INR in the range 2-3)
Study: 28637262
Drug: Counseling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling and nicotine replacement therapy
Study: 11736715
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg twice daily) and Ethambutol (15 mg/kg daily) for 3 months
Study: 9264222
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Gamimune-N, Miles Pharmaceutical Co) 200 mg/kg monthly for 1 year
Study: 3501750
Drug: Trimethoprim-sulphamethoxazole 160mg
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulphamethoxazole 160mg + 800mg twice daily for 3 days
Study: 2403756
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimens containing Adriamycin (doxorubicin) and mitomycin-C
Study: 25556355
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with zoledronic acid
Study: 25556355
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy without zoledronic acid
Study: 19615303
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy for dyssynergic defecation
Study: 19615303
Drug: Management including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management including education, counseling, diet, laxatives, and behavioral therapies
Study: 19615303
Drug: Surgical approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical approaches (e.g., stapled transanal rectal resection)
Study: 17256140
Drug: Post-treatment 131I
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment 131I scans
Study: 17256140
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-treatment scans
Study: 9667348
Drug: Ondansetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.5 mg
Study: 1679243
Drug: Ondansetron 1
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 1 mg
Study: 24631057
Drug: Ondansetron 2
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 2 mg
Study: 26051565
Drug: Curcumin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Study: 26051565
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules daily for seven days before menstruation and for three days after menstruation for three successive cycles)
Study: 18820592
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g (0.625 mg) conjugated estrogens (Premarin cream)
Study: 8033428
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg IVIG every 4 weeks
Study: 29332430
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml 0.9% saline (control)
Study: 26818484
Drug: Multi-faceted systems-based
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted systems-based package to improve penicillin delivery, aligned with elements of the Chronic Care Model, with continuous quality improvement processes including 3-monthly feedback to clinic staff.
Study: 11591494
Drug: Nicotine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (transdermal administration)
Study: 9715571
Drug: Sinus grafts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus grafts with implants
Study: 9715571
Drug: Various grafting
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various grafting materials and implant surfaces
Study: 7672877
Drug: Etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etodolac SR 600 mg u.i.d. for 8 weeks
Study: 7672877
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg u.i.d. for 8 weeks
Study: 23652896
Drug: Topical antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidant complex containing vitamins C and E and ferulic acid
Study: 9002803
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (no treatment)
Study: 12814453
Drug: Nafcillin 500
Normalized name: nafcillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafcillin 500 mg four times daily for 5 days
Study: 8795732
Drug: Acetazolamide (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (1,000 mg)
Study: 3711365
Drug: lithium +
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium + sulindac (300 mg/day)
Study: 22738715
Drug: Web CBT
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web CBT plus weekly telephone tracking
Study: 10770301
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin)
Study: 24498516
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (NS)
Study: 24498516
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (NS)
Study: 21816478
Drug: Clopidogrel resinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel resinate (75 mg) + aspirin (100 mg)
Study: 19030021
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 6-month depot of leuprorelin acetate
Study: 9291903
Drug: Daily repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily repeated application of fibrin glue (FG)
Study: 3113913
Drug: Buccal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal glyceryl trinitrate (Suscard)
Study: 3113913
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (Nitromex)
Study: 26661288
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (enoxaparin followed by warfarin)
Study: 24717254
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg administered at 10:30 pm
Study: 22381614
Drug: G-Bond Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond Plus (1-SEA) applied with phosphoric-acid etching to enamel
Study: 22381614
Drug: G-Bond Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond Plus (1-SEA) applied without phosphoric-acid etching to enamel
Study: 22381614
Drug: G-Bond Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond Plus (1-SEA) applied to dentine using self-etch protocol
Study: 22381614
Drug: G-Bond Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond Plus (1-SEA) applied to dentine using dry-bonding etch-and-rinse protocol
Study: 22381614
Drug: G-Bond Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Bond Plus (1-SEA) applied to dentine using wet-bonding etch-and-rinse protocol
Study: 18579976
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous HBB
Study: 11118471
Drug: RPR 109881A
Normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPR 109881A at 45 mg/m(2)
Study: 8886696
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Study: 8886696
Drug: Medrogestone 5
Normalized name: medrogestone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medrogestone 5 mg/day for 12 days during a 21-day cycle of transdermal estradiol (50 micrograms/day) for 6 cycles
Study: 3320259
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase therapy
Study: 6313523
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + H (Captopril 25 mg t.i.d. + Hydrochlorothiazide 15 mg t.i.d.)
Study: 6313523
Drug: H (Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: H (Hydrochlorothiazide 15 mg t.i.d.)
Study: 6313523
Drug: C (Captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (Captopril 25 mg t.i.d.)
Study: 17606561
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline injections
Study: 27194304
Drug: EGCG+RES (282
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG+RES (282 mg EGCG and 80 mg RES per day)
Study: 19460913
Drug: Patients attaining
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients attaining >=3 treatment targets (n = 91)
Study: 15529620
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (dosage and duration not specified)
Study: 11450676
Drug: Matching intravenous
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching intravenous and oral placebos
Study: 11450676
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone and oral doxycycline
Study: 2889522
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment group
Study: 29985281
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment group
Study: 23433590
Drug: Nevirapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (200 mg twice daily)
Study: 20151839
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg once daily)
Study: 18455221
Drug: Fixed-dose budesonide/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations twice daily)
Study: 29544162
Drug: Adjuvant zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjuvant zoledronic acid (ZOL) 4 mg administered by intravenous infusion every 3-4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5 for 5 years.
Study: 31326730
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (standard therapy)
Study: 18609474
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (DTFC) dosed twice daily
Study: 21802920
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (240 mg once daily)
Study: 31924316
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with docetaxel and prednisone administered every 3 weeks for six cycles
Study: 31924316
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with docetaxel and prednisone
Study: 26241775
Drug: MEDIC‐treatment (neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDIC‐treatment (neuromuscular exercise, education, diet, insoles, pain medication)
Study: 18219836
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol HFA MDI (180 microg; 2 actuations of 90 microg; n = 250)
Study: 16148283
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg daily)
Study: 11812271
Drug: Oral/metered-dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/metered-dose inhaler (oral/MDI) regimen
Study: 11812271
Drug: Intravenous/nebulizer (I.V./neb)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/nebulizer (I.V./neb) regimen
Study: 8557001
Drug: Rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium bromide (0.3 mg kg‐1 ED95)
Study: 7094971
Drug: Clomipramine (C1)
Normalized name: C1-INH
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (C1) at increasing dosage up to 150 mg per day
Study: 26535126
Drug: Naloxegol 12.5
Normalized name: naloxegol 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 12.5 mg
Study: 19825326
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (15 mg of sibutramine)
Study: 17657689
Drug: Photodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic treatment with Verteporfin
Study: 29361959
Drug: Supplemental parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental parenteral nutrition (PN) strategy
Study: 25644724
Drug: High-dose caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caffeine (loading 40 mg/kg/day and maintenance 20 mg/kg/day)
Study: 21128833
Drug: Anomia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anomia therapy involving cueing to improve retrieval of nouns, specific dosage and duration not mentioned.
Study: 12406041
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg t.i.d.)
Study: 9484423
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg daily
Study: 9484423
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg and 400 mg daily
Study: 8159602
Drug: Picenadol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picenadol 30 mg
Study: 6392354
Drug: Codeine 90
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 90 mg
Study: 2831758
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg captopril (group C; n = 12)
Study: 29072245
Drug: Extended amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended amoxicillin/clavulanic acid, 1 gram pre-operatively and then 625 mg BD for 5 days
Study: 29072245
Drug: Prophylactic amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic amoxicillin/clavulanic acid, 1 gram pre-operatively only
Study: 23935833
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills (described as Tylenol)
Study: 19737592
Drug: E. amoenum
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. amoenum aqueous extract (500 mg/day)
Study: 11032271
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg x kg(‐1) tramadol (Group 1)
Study: 9515971
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean dose 55 mg/day)
Study: 30908085
Drug: Gaze-Contingent Music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaze-Contingent Music Reward Therapy (GC-MRT)
Study: 25362524
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg)
Study: 25362524
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg) plus ten applications of a vaginal probiotic (Lactobacillus acidophilus, L. rhamnosus, Streptococcus thermophilus, L. delbrueckii subsp. bulgaricus) starting on the fifth day after azole treatment
Study: 23557551
Drug: Aliskiren (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150 mg/d)
Study: 1411408
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/d)
Study: 21241965
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin and 25 mg rofecoxib
Study: 15984630
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% cream and gel
Study: 22174350
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg subcutaneously)
Study: 10775736
Drug: Immediate-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release oxybutynin
Study: 9034759
Drug: Pharmaton Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaton Capsules (multivitamins plus ginseng extract G115)
Study: 9034759
Drug: Multivitamin capsules
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin capsules (without ginseng)
Study: 2005078
Drug: Fluoxetine a.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine a.m. (20 to 80 mg daily for 5 weeks)
Study: 2005078
Drug: Fluoxetine p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine p.m. (20 to 80 mg daily for 5 weeks)
Study: 6848406
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid (13 mg/kg . day)
Study: 17377800
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (ITS)
Study: 27442803
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous patient-controlled analgesia (iv. PCA)
Study: 22410815
Drug: Diet soda
Normalized name: Magadi soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet soda (240 mL cola-flavored caffeine-free)
Study: 2722310
Drug: Metoclopramide, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide, 20 mg
Study: 2722310
Drug: BRL 24924,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 24924, 2 mg
Study: 23472599
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (n = 26)
Study: 23472599
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (n = 20)
Study: 21809025
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with FOLFOX regimen (oxaliplatin 100 mg/m² on day 1, leucovorin 200 mg/m² on day 1, 5-fluorouracil 2000 mg/m² as a 48-h continuous infusion for up to six courses in the 1st year after transplantation)
Study: 19783561
Drug: Praneem polyherbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praneem polyherbal vaginal tablets
Study: 1293915
Drug: Combined multidrug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined multidrug treatment (MDT) and immunotherapy with heat killed Mycobacterium w or BCG, administered intradermally every six months.
Study: 1293915
Drug: Multidrug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug treatment (MDT) alone
Study: 3838188
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy plus extensive radiotherapy (mantle and paraaortic areas)
Study: 3838188
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy plus involved field radiotherapy
Study: 3838188
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy plus extensive radiotherapy
Study: 30973337
Drug: SFSW intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SFSW intervention (Web-based training program with 11 weekly themes and associated telephone sessions)
Study: 25220844
Drug: Tyrosine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (300 mg/kg)
Study: 18444444
Drug: Dronabinol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (20 mg)
Study: 21890886
Drug: 6% w/v
Normalized name: PROPYLENE GLYCOL 0.6 g in 100 mL OPHTHALMIC LIQUID [VISTA MEIBO TEARS Propylene Glycol 0.6% w/v Advanced Dry Eye Relief Lubricating Drops 10 ml]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% w/v hydroxyethyl starch solution (HES)
Study: 21890886
Drug: Hartmann (crystalloid)
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann (crystalloid) solution (HS)
Study: 1863724
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion
Study: 19695776
Drug: Internet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet treatment group (8 weeks of online modules including relaxation training, cognitive strategies, parent operant techniques, communication strategies, and sleep and activity interventions)
Study: 17908057
Drug: Periosteal stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periosteal stimulation therapy (PST)
Study: 12426738
Drug: Low-dose spiral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose spiral CT screening